POLYPHOR AG sees a downgrade to Negative on account of less fundamental stars
The independent financial analyst theScreener just lowered the general evaluation of POLYPHOR AG (CH), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date September 28, 2021, the closing price was CHF 2.00 and its target price was estimated at CHF 1.00.Polyphor AG is a Switzerland-based company, which is engaged in the development of novel antibiotics and other efficacious therapies. The Company's medicines pipeline includes Murepavadin (POL7080), a novel class of specific outer membrane protein targeting antibiotic to treat resistant Pseudomonas infections; the Outer Membrane Protein Targeting Antibiotics (OMPTA), which provides treatment options to treat infections caused by Gram-negative bacteria; POL6014 is inhaled elastase inhibitor for the treatment of Cystic Fibrosis and other neutrophilic lung diseases, as well as Balixafortide (POL6326) is a blocker of tumor growth and metastasis. The Company develops Macrocycle discovery platform, which includes library consisted of over 50,000 single, untagged, individually purified peptidic and non-peptidic macrocycles readily amenable to all screening formats, including binding, enzymatic, cellular, pathway and phenotypical.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.